Dataset Information


A thermo-responsive protein treatment for dry eyes.

ABSTRACT: Millions of Americans suffer from dry eye disease, and there are few effective therapies capable of treating these patients. A decade ago, an abundant protein component of human tears was discovered and named lacritin (Lacrt). Lacrt has prosecretory activity in the lacrimal gland and mitogenic activity at the corneal epithelium. Similar to other proteins placed on the ocular surface, the durability of its effect is limited by rapid tear turnover. Motivated by the rationale that a thermo-responsive coacervate containing Lacrt would have better retention upon administration, we have constructed and tested the activity of a thermo-responsive Lacrt fused to an elastin-like polypeptide (ELP). Inspired from the human tropoelastin protein, ELP protein polymers reversibly phase separate into viscous coacervates above a tunable transition temperature. This fusion construct exhibited the prosecretory function of native Lacrt as illustrated by its ability to stimulate ?-hexosaminidase secretion from primary rabbit lacrimal gland acinar cells. It also increased tear secretion from non-obese diabetic (NOD) mice, a model of autoimmune dacryoadenitis, when administered via intra-lacrimal injection. Lacrt ELP fusion proteins undergo temperature-mediated assembly to form a depot inside the lacrimal gland. We propose that these Lacrt ELP fusion proteins represent a potential therapy for dry eye disease and the strategy of ELP-mediated phase separation may have applicability to other diseases of the ocular surface.

PROVIDER: S-EPMC4456095 | BioStudies |

REPOSITORIES: biostudies

Similar Datasets

| S-EPMC3844047 | BioStudies
2013-01-01 | S-EPMC3604909 | BioStudies
| S-EPMC3460390 | BioStudies
| S-EPMC3441044 | BioStudies
| S-EPMC2712882 | BioStudies
2012-01-01 | S-EPMC4113189 | BioStudies
2013-01-01 | S-EPMC3806342 | BioStudies
| S-EPMC6203219 | BioStudies
| S-EPMC3652637 | BioStudies
| S-EPMC4836376 | BioStudies